Envista (NYSE:NVST) announced today that the FDA cleared the Nobel Biocare N1 implant system of instruments, prosthetic components and surgical protocols.
The N1 system includes an implant designed for immediate placement and predictable insertion torques, providing a trioval conical connection for the abutment to slide into place. Additionally, the system has an emergence profile designed for soft tissue maintenance.
It includes the OsseoShaper implant for redefining site preparation and reshaping implantology with optimized workflows, greater patient comfort and faster treatment times, according to a news release. The OsseoShaper “shapes” the osteotomy at a low speed and without irrigation to reduce noise and vibration compared to conventional drilling protocols.
“The demand for high-quality patient-centric solutions is higher than ever and the Nobel Biocare N1 system enables clinicians to set a new standard in personalizing, digitizi…